Ability of Lactobacillus fermentum to overcome host α-galactosidase deficiency, as evidenced by reduction of hydrogen excretion in rats consuming soya α-galacto-oligosaccharides
- 7.1k Downloads
Soya and its derivatives represent nutritionally high quality food products whose major drawback is their high content of α-galacto-oligosaccharides. These are not digested in the small intestine due to the natural absence of tissular α-galactosidase in mammals. The passage of these carbohydrates to the large intestine makes them available for fermentation by gas-producing bacteria leading to intestinal flatulence. The aim of the work reported here was to assess the ability of α-galactosidase-producing lactobacilli to improve the digestibility of α-galacto-oligosaccharides in situ.
Gnotobiotic rats were orally fed with soy milk and placed in respiratory chambers designed to monitor fermentative gas excretion. The validity of the animal model was first checked using gnotobiotic rats monoassociated with a Clostridium butyricum hydrogen (H2)-producing strain. Ingestion of native soy milk by these rats caused significant H2 emission while ingestion of α-galacto-oligosaccharide-free soy milk did not, thus validating the experimental system. When native soy milk was fermented using the α-galactosidase-producing Lactobacillus fermentum CRL722 strain, the resulting product failed to induce H2 emission in rats thus validating the bacterial model. When L. fermentum CRL722 was coadministered with native soy milk, a significant reduction (50 %, P = 0.019) in H2 emission was observed, showing that α-galactosidase from L. fermentum CRL722 remained active in situ, in the gastrointestinal tract of rats monoassociated with C. butyricum. In human-microbiota associated rats, L. fermentum CRL722 also induced a significant reduction of H2 emission (70 %, P = 0.004).
These results strongly suggest that L. fermentum α-galactosidase is able to partially alleviate α-galactosidase deficiency in rats. This offers interesting perspectives in various applications in which lactic acid bacteria could be used as a vector for delivery of digestive enzymes in man and animals.
KeywordsLactic Acid Bacterium Raffinose Stachyose Respiratory Chamber Human Faecal Microbiota
Brain heart infusion
Lactic acid bacteria
Man Rogosa Sharp
The nutritional value of soya-derived products is high since the amino acid profile of soy protein corresponds more closely to human requirements than most other plant proteins . In recognition of this high quality, the US Department of Agriculture issued a ruling in 2000 allowing soy protein to completely replace animal protein in the Federal School Lunch Program . Soy proteins have also been shown to reduce the incidence of cardiovascular disease  and, in this context, the US Food and Drug Administration has approved a health claim for the cholesterol-lowering effect of soy proteins . Other key benefits of soya derive from its high content of isoflavones which are thought to exert a range of biological effects against hormone-dependent diseases such as breast and prostate cancer, menopausal symptoms, cardiovascular diseases, and osteoporosis . Taken together, these reported health benefits, along with growing consumer preference for plant-derived food rather than meat, have led to an increasing demand for soy products . However, in addition to these positive properties, soya does have one negative characteristic limiting its use in human nutrition. As is the case with other legumes, soya contains high levels of the α-galacto-oligosaccharides (α-GOS) raffinose and stachyose that are composed of one sucrose moiety and one or two galactose moieties, respectively. Since mammals are deficient in the enzyme α-galactosidase (α-Gal), which hydrolyses the α-1, 6 linkages found in these sugars, α-GOS are not digested in the upper gastrointestinal tract and reach the large intestine where they are fermented by the resident microbiota. The resulting production of fermentative gases can induce abdominal pain as well as the social embarrassment associated with flatulence [7, 8]. Such negative aspects reduce the acceptability of soy products as a major human food source .
One means of avoiding this problem could be to remove α-GOS from the raw agricultural products. This could be achieved by fermenting soya-derived products, such as soy milk, using food grade bacteria that are able to catabolize α-GOS into digestible carbohydrates. Lactic acid bacteria (LAB) have long been used in food processing, and some of these are able to produce α-Gal, making them good candidates to fulfil this task [10, 11, 12]. This approach is promising for the manufacture of soy yoghurts since some LAB are also able to reduce the concentration of the aldehydes responsible for the undesirable beany flavour of soy milk . However, this strategy is limited to food products that are to be fermented by LAB. For soya and α-GOS-rich food products that are not intended to be fermented by LAB, another method of reducing the quantity of gas-producing substrates would be to use LAB as a vehicle for delivering α-Gal to the small intestine, allowing the enzyme to hydrolyse undigested α-GOS prior to their passage to the large intestine. In previous experiments, we selected the Lactobacillus (L.) fermentum CRL722 strain for its high α-Gal activity, which allowed it to degrade raffinose and stachyose in vitro [11, 14]. Following oral administration of live cells or cell-free extracts of this strain, we were able to detect a short-lived α-Gal activity in the small intestinal chyme of conventional rats .
The present study was designed to assess the efficiency of L. fermentum CRL722 to reduce gas production in rats consuming α-GOS. Gnotobiotic rats which were monoassociated with Clostridium (C.) butyricum, a bacterial species known to produce large amounts of gas from carbohydrate fermentation, were first used as an animal model. In a second series of experiments, we investigated the effect of L. fermentum CRL722 in a microbiological environment similar to the human gastrointestinal tract, using human microbiota-associated rats. In all the trials, L. fermentum CRL722 was consumed as a bolus of live cells, and H2 excreted through breath and flatus was used as a biomarker of gas production in the gastrointestinal tract.
A model experimental system to assess the potential of α-Gal-producing lactobacilli to improve α-GOS digestion in rats
α-Gal-producing L. fermentum CRL722 is able to remove flatus-generating α-GOS both in soy milk and in the gastrointestinal tract of rats monoassociated with C. butyricum DSM10702
α-Gal-producing L. fermentum CRL722 also exerts a digestive activity in human microbiota-associated rats
The primary aim of this work was to assess the potential of LAB to facilitate the digestion of soy α-GOS through their α-Gal activity. In this context, we have previously characterized α-Gals from various lactobacilli, and one from L. fermentum CRL722 appeared to be the most active . The present work focused on assessing the ability of the α-Gal producing L. fermentum CRL722 strain to improve the digestibility of soy α-GOS via its α-Gal activity expressed either during soy milk fermentation or in the gastrointestinal tract of rats. Using an animal model consisting of gnotobiotic rats monoassociated with an H2-producing C. butyricum strain, we first showed that depletion of α-GOS from soy milk using L. fermentum CRL722 as a starter greatly decreased sugar fermentation in the gastrointestinal tract of rats as shown by an important reduction in H2 excretion. We further showed that L. fermentum CRL722, when coadministered with soy milk rich in α-GOS, greatly reduced H2 excretion derived from α-GOS fermentation. This suggests that L. fermentum CRL722 α-Gal is active and available in the intestine to degrade α-GOS. In our animal model consisting of gnotobiotic rats monoassociated with an H2-producing C. butyricum strain, we observed that L. fermentum CRL722 was able to colonize the gastrointestinal tract. This means that at least a fraction of the L. fermentum CRL722 inoculum survived the conditions encountered in the upper part of the gastro-intestinal tract and found an appropriate environment to multiply in the large intestine, despite the presence of a resident species. As a consequence, the observed reduction in gas production may have been caused either by the metabolic activity of L. fermentum CRL722 in the small intestine or as a result of the strain colonizing the large intestine and competing there with C. butyricum for α-GOS utilization. To assess which of these mechanisms applied, we went on to use another animal model consisting of rats harbouring a human faecal microbiota. This latter was expected to form a natural defence barrier , preventing L. fermentum CRL722 to settle in the large intestine. Using this system, the α-GOS amount previously administered to Cb rats did induce a lower H2 emission than that monitored in Cb rats. This may result either from a poor level of gas producing bacteria in the used human microbiota, or, most likely, from the activity of H2-consuming microorganisms such as methanogenic archeae, sulfatoreducing or reductive acetogenic bacteria. Therefore, the α-GOS amount administered to HMA rats was increased 3 fold. This corresponds to an average intake of 4.5 g of legumes which is a physiologically acceptable dose for rats. Under these conditions, L. fermentum CRL722 still improved α-GOS digestibility although, as expected, it was unable to colonize the large intestine. This strongly suggests that the enzyme activity occurs in the small intestinal compartment. In further preliminary experiments to distinguish between L. fermentum CRL722 α-GOS utilization and delivery of α-Gal activity by L. fermentum CRL722, we used another α-Gal+ L. fermentum strain that is deficient in α-GOS transport. Interestingly, this L. fermentum strain exhibited an in vivo effect similar to that of L. fermentum CRL722, suggesting that the latter strain acts through delivery of α-Gal to the small intestine rather than via α-GOS utilization (data not shown). This observation is consistent with a previous study in which we found that the majority of L. fermentum CRL722 cells did not survive the duodenal portion of the small intestine, as has been found for another LAB, Lactococcus lactis [15, 19]. In this latter work, a significant, although short-lived, α-Gal activity was found in the duodenum of rats fed L. fermentum CRL722. It appears that this short life of α-Gal is sufficient to allow digestion of the α-GOS present in the diet, as shown by the present work.
The model presented here should allow further elucidation of both the mechanisms and the parameters that govern the expression of LAB enzymatic activities in vivo. Few other studies have been performed in this area. Lactococcus lactis strains genetically engineered to produce lipase have been shown to be capable of alleviating a lipase pancreatic insufficiency caused by ligation of the pancreatic duct in pigs . Other studies have suggested that LAB improve lactose digestion of dairy products in lactase-deficient individuals by delivery of β-galactosidase to the gastrointestinal tract . However, a recent systematic review stressed the variability found in these studies and the difficulty in drawing definitive conclusions on the positive effect of LAB in lactase supplementation . The α-Gal host deficiency retained in the present model system is, in contrast to lipase and lactase deficiencies, constitutive in mammals; this model should therefore reduce inter-individual variation. Furthermore, the animal model described here makes it possible to perform quick analyses. This will allow the effect of different parameters such as the influence of the LAB vehicle (susceptibility to lysis, colonizing ability, etc.) and of the mode of administration of LAB to be studied.
This study showed that a given host enzyme deficiency can be supplemented by orally administered LAB that produce this enzyme at high level. This type of work opens up the possibility of using LAB vehicles for delivery of other digestive enzymes to the digestive tract. LABs have great potential in this field. First, since these bacteria have long been ingested by man in fermented products, the mucosal digestive immune system has developed a tolerance to these bacteria, some of which are commensal . Furthermore, LABs form a heterogeneous family of bacteria originating from various ecological niches. These bacteria therefore have a diverse range of enzymatic activities required for their adaptation to those niches . Finally, their designation as GRAS (Generally Recognized As Safe) by the US Food and Drug Administration, positions them as particularly well-suited organisms for this type of application.
Chemicals and culture media
Soy milk was kindly provided by Lallemand Inc. (Montreal, Canada). Raffinose, stachyose, p-nitrophenyl-α-D-galactopyranoside (pNPG) and α-Gal from green coffee beans were purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France). 5-Bromo-4-chloro-3-indolyl α-D-galactopyranoside (X-α-Gal) was from Research Organics (Cleveland, OH). Man Rogosa Sharp (MRS) medium was prepared as described elsewhere , Brain Heart Infusion (BHI) medium was purchased from Difco (Detroit, MI) and peptone water contained 1 g/l peptone (Difco).
Lactobacillus fermentum CRL722 was obtained from the Culture Collection of the Centro de Referencia para Lactobacilos (CERELA, Tucuman, Argentina) and has been characterized elsewhere [10, 11, 14]. A spontaneous rifampicin-resistant (RifR) derivative was checked for the α-Gal+ phenotype, using the chromogenic substrate X-α-Gal. Briefly, bacteria were grown on MRS agar plates containing 0.5 % (w/v) glucose and spread with 50 μl of a 20 g/l X-α-Gal solution using glass beads. Quantification of α-Gal activity was performed according to a previously described method , using pNPG as a substrate. No significant differences in α-Gal activity could be found between the RifR derivative and the parental strain. L. fermentum CRL722 and its RifR derivative were routinely grown at 37°C under anaerobiosis in MRS medium, supplemented with 100 μg/ml rifampicin when required. Clostridium butyricum DSM10702 was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany); it originates from the intestine of swine and is the type strain of the species. It was chosen because of its ability to produce large amounts of gas, namely hydrogen and carbon dioxide, from raffinose and stachyose fermentation . C. butyricum DSM10702 was routinely grown in BHI medium at 37°C under anaerobiosis. All strains were stored at -80°C in 20 % glycerol/80 % culture medium (v/v). The human faecal microbiota originated from stools provided by a 37-year-old Caucasian woman with Western dietary habits who had not taken any laxative or antibiotic during the preceeding three months.
Germ-free 10–12 week old male F344 rats (mean weight 266 g (SD 19 g)) were obtained from the Germ-Free Rodent Breeding Facilities of UR910 – Unit of Ecology and Physiology of the Digestive Tract (INRA, Jouy-en-Josas, France). They were randomly separated into two groups and housed in a series of Plexiglas® isolators fitted with a double-door sealed transfer system (Ingénia, Vitry-sur-Seine, France). Throughout the study, rats were kept in pairs in standard macrolon cages with sterile wood shavings as bedding. They were given free access to autoclaved tap water and to a pelleted semi-synthetic diet (Scientific Animal Food and Engineering, Augy, France) sterilized by γ-irradiation at 45 kGy (IBA Mediris, Fleurus, Belgium) . Isolators were maintained under controlled conditions of light (07.00–19.00 h), temperature (20–22°C) and humidity (45–55 %).
Respiratory chambers and H2 excretion analysis
Preparation of the L. fermentum CRL722 inoculum and the α-GOS rich- and α-GOS-free soy milk
In order to selectively quantify L. fermentum CRL722 in the rat faeces, the spontaneous RifR derivative was used in the animal trials. The RifR strain was grown overnight in MRS broth. The following morning, bacterial cells were pelleted and suspended in peptone water at a concentration of 4 × 109 CFU/ml for immediate use. Soy milk was sterilized by autoclaving (10 min, 110°C) and enriched with aqueous sterile stock solutions of raffinose and stachyose. Final concentrations of raffinose and stachyose in soy milk were 48 and 76 mM, respectively, for rats monoassociated with C. butyricum DSM10702 and 144 and 228 mM, respectively, for human microbiota-associated rats. The α-GOS-free soy milk was prepared by incubating the α-GOS-enriched soy milk with coffee bean α-Gal (5 % of a 1 IU/ml stock solution, v/v) at 37°C for 12 h. The enzyme was then inactivated by heat treatment (10 min, 100°C) and total degradation of raffinose and stachyose was confirmed by HPLC (Waters 625LC system, Mildford, MA) using a Bio-Rad Aminex HPX-87H column (Bio-Rad Labs, Hercules, CA). Elution was performed at 25°C with an isocratic flow of 0.4 ml/min 0.005 N-phosphoric acid. Eluted sugars were detected by differential refractometry (Waters 410). Sugar quantification was performed using the external standard method . Both soy milk preparations were stored at -20°C until use.
Experimental design of the rat trials
All procedures were carried out in accordance with the European guidelines for the care and use of laboratory animals. Animals of one group (n = 12) were inoculated intragastrically with 1 ml of an overnight culture of C. butyricum DSM10702 (1010 CFU/ml) using a stainless-steel stomach tube; they were subsequently designated as Cb (C. butyricum) rats. Animals belonging to the other group (n = 4) were colonized with a faecal suspension made from the stools of the human donor, as described previously . Briefly, fresh stools were introduced into an anaerobic glove box and dispersed in BHI broth (1 %, w/v); aliquots of the suspension were subsequently transferred to the isolators and given to the rats with a stomach tube (1 ml/rat); these rats were designated as HMA (human microbiota-associated) rats. The experiment began after a 3-wk acclimatization period to the new bacterial status. First, fresh faecal pellets were collected from each rat to confirm the microbial colonization of the gastrointestinal tract. Serial 10-fold suspensions, prepared from faecal samples of Cb rats, were spread onto BHI agar plates which were then incubated under anoxic conditions at 37°C for 48 h prior to colony counting. In HMA rats, the microbiological abundance and diversity of the faeces was assessed by light microscopic examination. The Cb rats were then randomly allocated to three groups (n = 4), namely Cb-A, Cb-B and Cb-C (Fig. 5). In all groups, each rat was successively fed orally with (i) peptone water to determine the basal level of H2 excretion, (ii) the α-GOS-free soy milk as a negative control, and (iii) the α-GOS-rich soy milk as a positive control. The fourth treatment differed according to the group: the Cb-A rats were fed with L. fermentum CRL722 alone to assess whether the bacterium per se, affected H2 excretion (strain control); the Cb-B rats received the α-GOS-rich soy milk previously incubated with the L. fermentum inoculum (2 %, v/v) for 16 h at 37°C under anaerobiosis; finally, the Cb-C rats received the α-GOS-rich soy milk along with the L. fermentum inoculum. In the case of the HMA rats, they received successively (i) the α-GOS-free soy milk (negative control), (ii) the α-GOS-rich soy milk (positive control), and (iii) the combination of the α-GOS-rich soy milk and the L. fermentum inoculum. In both Cb- and HMA groups, a one-week wash out period was allowed between each treatment. The trials were performed as follows. After overnight deprivation of food, the rats were fed with a 2 ml-mixture, the composition of which is detailed in Fig. 5, using a stainless-steel stomach tube. Immediately after feeding, each rat was transferred to a respiratory chamber where it remained for up to 9 h, and air samples were taken in duplicate every 90 min for H2 analysis. Rats were thereafter returned to their original isolators and fresh faecal pellets were collected at intervals for 72 h to enumerate the L. fermentum population.
Enumeration of L. fermentum CRL722 in rat faeces
Freshly-collected faecal pellets were thoroughly homogenized in peptone water and serial 10-fold dilutions were prepared. These were spread onto MRS agar plates that contained rifampicin at 100 μg/ml, and plates were incubated under anoxia at 37°C for 48 h prior to colony counting. Under these conditions, only the RifR L. fermentum derivative could grow while both C. butyricum and the microbiota of human origin were inhibited. Bacterial counts were expressed as CFU/g of faeces.
Calculations and statistical analyses
All data are expressed as mean values of H2 excretion per 100 g of rat metabolic weight (MW; live weight to the 0.75 power) and standard errors of the mean. In each group of rats, the effect of the treatments on H2 excretion was assessed using ANOVA for repeated measurements. When ANOVA indicated significant differences, treatments were compared using the Student-Newman-Keuls multiple comparison test. Statistical significance was set at P < 0.05. Calculations were performed using the SigmaStat software package (Systat Software Inc., Richmond, CA).
This work was supported by the European Community under the Research and Technological Development program Quality of Life and Management of Living Resources 'Nutra Cells' (QLK1-CT-2000-01376), by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, Argentina), by Agencia de Promoción Científica y Tecnológica, CIUNT (Argentina) and by ECOS-Sud (France). We are grateful to Marc Weber for preparing Fig. 4 and to Alan Duncan and Maarten van de Guchte for revising the English style of the manuscript. We thank Anthony Bouclet for technical assistance with the gnotobiotic rats. We appreciate helpful discussion with Elise Durant and Aurelia Hiron as well as critical reading of the manuscript by Lionel Rigottier-Gois.
- 2.USDA: Modification of the vegetable protein products requirements for the national school lunch program, school breakfast program, summer food service program and child and adult care food program. 2000, Report of the U. S. Department of AgricultureGoogle Scholar
- 4.FDA: Food labelling, health claims, soy protein, and coronary heart disease. 1999, 699:733-Google Scholar
- 6.www.soyfoods.org.Google Scholar
- 8.Smiricky-Tjardes MR, Grieshop CM, Flickinger EA, Bauer LL, Fahey GC: Dietary galactooligosaccharides affect ileal and total-tract nutrient digestibility, ileal and fecal bacterial concentrations, and ileal fermentative characteristics of growing pigs. J Anim Sci. 2003, 81 (10): 2535-2545.PubMedGoogle Scholar
- 11.LeBlanc JG, Garro MS, Silvestroni A, Connes C, Piard JC, Sesma F, Savoy de Giori G: Reduction of alpha-galactooligosaccharides in soyamilk by Lactobacillus fermentum CRL 722: in vitro and in vivo evaluation of fermented soyamilk. J Appl Microbiol. 2004, 97 (4): 876-881. 10.1111/j.1365-2672.2004.02389.x.CrossRefPubMedGoogle Scholar
- 20.Drouault S, Juste C, Marteau P, Renault P, Corthier G: Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl Environ Microbiol. 2002, 68 (6): 3166-3168. 10.1128/AEM.68.6.3166-3168.2002.PubMedCentralCrossRefPubMedGoogle Scholar
- 26.Church FC, Meyers FP, Srinivasan VR: Isolation and characterization of alpha-galactosidase from Pichia guilliermondii. Developments in Industrial Microbiology. Edited by: Underkofler LA, Wulf ML. 1980, Airlington, Virginia , 21: 339-348.Google Scholar
- 27.Cato EP, George WL, Finegold SM: Genus Clostridium Prazmowski 1880, 23AL. Bergey's Manual of Systematic Bacteriology. Edited by: PHA S. 1986, Baltimore, MD, USA , Williams & Wilkins, 2: 1141-1200.Google Scholar
- 28.Lan A, Bruneau A, Philippe C, Rochet V, Rouault A, Herve C, Roland N, Rabot S, Jan G: Survival and metabolic activity of selected strains of Propionibacterium freudenreichii in the gastrointestinal tract of human microbiota-associated rats. Br J Nutr. 2007, 97 (4): 714-724. 10.1017/S0007114507433001.CrossRefPubMedGoogle Scholar
- 30.Djouzi Z, Andrieux C, Degivry MC, Bouley C, Szylit O: The association of yogurt starters with Lactobacillus casei DN 114.001 in fermented milk alters the composition and metabolism of intestinal microflora in germ-free rats and in human flora-associated rats. J Nutr. 1997, 127 (11): 2260-2266.PubMedGoogle Scholar
- 31.Djouzi Z, Andrieux C, Pelenc V, Somarriba S, Popot F, Paul F, Monsan P, Szylit O: Degradation and fermentation of alpha-gluco-oligosaccharides by bacterial strains from human colon: in vitro and in vivo studies in gnotobiotic rats. J Appl Bacteriol. 1995, 79 (2): 117-127.CrossRefPubMedGoogle Scholar
- 32.Lecoz Y, Morel MT, Bousseboua H, Dufour C, Szylit O: Mise au point d'une chambre respiratoire connectée sur isolateur pour la mesure in vivo des gaz de fermentation chez l'animal gnotoxénique [Development of a respiratory chamber and its connexion with an isolator: a method to measure the in vivo production of fermentation gas by gnotobiotic animals]. Sci Tech Anim Lab. 1989, 14: 35-39.Google Scholar
- 33.Sanchez-Mata MC, Penuela-Teruel MJ, Camara-Hurtado M, Diez-Marques C, Torija-Isasa ME: Determination of Mono-, Di-, and Oligosaccharides in Legumes by High-Performance Liquid Chromatography Using an Amino-Bonded Silica Column. J Agric Food Chem. 1998, 46 (9): 3648-3652. 10.1021/jf980127w.CrossRefGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.